Literature DB >> 11514224

Proteasome inhibitors: from research tools to drug candidates.

A F Kisselev1, A L Goldberg.   

Abstract

The 26S proteasome is a 2.4 MDa multifunctional ATP-dependent proteolytic complex, which degrades the majority of cellular polypeptides by an unusual enzyme mechanism. Several groups of proteasome inhibitors have been developed and are now widely used as research tools to study the role of the ubiquitin-proteasome pathway in various cellular processes, and two inhibitors are now in clinical trials for treatment of multiple cancers and stroke.

Entities:  

Keywords:  Non-programmatic

Mesh：

Substances：

Year:  2001        PMID： 11514224     DOI： 10.1016/s1074-5521(01)00056-4

Source DB:  PubMed          Journal:  Chem Biol        ISSN： 1074-5521


  344 in total

1.  Antitrypanosomal activities of proteasome inhibitors.

Authors:  Njinkeng Joseph Nkemngu; Joseph Nkemgu-Njinkeng; Vera Rosenkranz; Michael Wink; Dietmar Steverding
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

2.  Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro.

Authors:  I R Garrett; D Chen; G Gutierrez; M Zhao; A Escobedo; G Rossini; S E Harris; W Gallwitz; K B Kim; S Hu; C M Crews; G R Mundy
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

3.  A concise, total synthesis of the TMC-95A/B proteasome inhibitors.

Authors:  Brian K Albrecht; Robert M Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-26       Impact factor: 11.205

4.  A novel mechanism for mitogen-activated protein kinase localization.

Authors:  Eric Bind; Yelena Kleyner; Dorota Skowronska-Krawczyk; Emily Bien; Brian David Dynlacht; Irma Sánchez
Journal:  Mol Biol Cell       Date:  2004-07-21       Impact factor: 4.138

Review 5.  The kinder side of killer proteases: caspase activation contributes to neuroprotection and CNS remodeling.

Authors:  B McLaughlin
Journal:  Apoptosis       Date:  2004-03       Impact factor: 4.677

6.  Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo.

Authors:  Haijun Zhang; Di Chen; Jonathan Ringler; Wei Chen; Qiuzhi Cindy Cui; Stephen P Ethier; Q Ping Dou; Guojun Wu
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

Review 7.  Update in new anabolic therapies for osteoporosis.

Authors:  Ernesto Canalis
Journal:  J Clin Endocrinol Metab       Date:  2010-04       Impact factor: 5.958

8.  Nature of pharmacophore influences active site specificity of proteasome inhibitors.

Authors:  Michael Screen; Matthew Britton; Sondra L Downey; Martijn Verdoes; Mathias J Voges; Annet E M Blom; Paul P Geurink; Martijn D P Risseeuw; Bogdan I Florea; Wouter A van der Linden; Alexandre A Pletnev; Herman S Overkleeft; Alexei F Kisselev
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

9.  Inhibitors of the proteasome stimulate the epithelial sodium channel (ENaC) through SGK1 and mimic the effect of aldosterone.

Authors:  Morag K Mansley; Christoph Korbmacher; Marko Bertog
Journal:  Pflugers Arch       Date:  2017-08-31       Impact factor: 3.657

10.  Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis.

Authors:  S S Xing; C C Shen; M P Godard; J J Wang; Y Y Yue; S T Yang; Q Zhao; S B Zhang; T X Wang; X L Yang; P Delafontaine; Y He; Y H Song
Journal:  Biochem Biophys Res Commun       Date:  2014-02-10       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.